Affymetrix's

Investor's Business Daily

Affymetrix's (AFFX) 1st-of-a-kind blood test to predict intellectual disabilities in infants was approved by the FDA. The lab test detects chromosome variations linked to Down syndrome and other developmental disorders, and is expected to enable earlier treatment. Affymetrix slipped 2.3% to 9.26.

View Comments (0)